Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

lucatumumab

A monoclonal antibody directed against the B-cell surface antigen CD40 with potential antineoplastic activity. Lucatumumab binds to and inhibits CD40, thereby inhibiting CD40 ligand-induced cell proliferation and triggering cell lysis via antibody-dependent cellular cytotoxicity (ADCC) in cells overexpressing CD40. CD40, an integral membrane protein found on the surface of B lymphocytes, is a member of the tumor necrosis factor receptor superfamily and is highly expressed in a number of B-cell malignancies.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:monoclonal antibody CHIR-12.12
Abbreviation:MOAB CHIR-12.12
Code name:CHIR-12.12
HCD-122
Chemical structure:immunoglobulin G1, anti-(human CD40 (antigen)) (human monoclonal CHIR-12.12 heavy chain), disulfide with human monoclonal CHIR-12.12 light chain, dimer
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search